Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues ‘Charity’

Progression-free survival reasonably predicts overall survival in advanced prostate cancer and could bring new therapies to patients about 2 years faster if used as the primary endpoint in clinical studies. (University College London, Journal of Clinical Oncology)

Adding mental health support to cancer care reduced patients’ pain, depression, and fatigue and improved quality of life. (University of Pittsburgh Medical Center, The Lancet)

Worsening metabolic syndrome may increase the risk of developing cancer. (Cancer)

The Environmental Protection Agency announced a final rule to limit ethylene oxide emissions to reduce the risk of cancer among people living near commercial sterilization facilities.

CAR T-cell therapy targeting two different proteins showed early promise for slowing the growth of recurrent glioblastoma. (Penn Medicine, Nature Medicine)

Nurix Therapeutics announced that the FDA has lifted a partial clinical hold on a phase I trial of NX-2127, the company’s oral bifunctional therapy for B-cell malignancies.

Could data from internet searches be used to detect gynecologic cancers earlier, possibly well before a patient sees a doctor for evaluation? (Imperial College London, BMC Public Health)

About a third of patients with recurrent/metastatic cervical cancer responded to the investigational antibody-drug conjugate (ADC) disitamab vedotin, RemeGen announced.

Patients with heavily pretreated platinum-resistant ovarian cancer and no prior exposure to pegylated liposomal doxorubicin had significantly improved survival when treated with tumor-treating fields therapy and paclitaxel. (BioSpace)

Patients with relapsed/refractory diffuse large B-cell lymphoma lived significantly longer with the ADC brentuximab vedotin (Adcetris) plus lenalidomide (Revlimid) and rituximab (Rituxan) versus lenalidomide-rituximab alone, Pfizer announced.

The Federal Trade Commission and 10 states have sued the sham charity Cancer Foundation Fund International for deceptive practices that persuaded donors to contribute more than $18 million.

Decisions in two cases pending before the Supreme Court and one in an appeals court could have a profound impact on cancer care delivery in the U.S. (Association for Clinical Oncology)

Please enable JavaScript to view the

comments powered by Disqus.